So-young Yeo
Seoul, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
PRRX1 is a master transcription factor of stromal fibroblasts for myofibroblastic lineage progression.
Journal: Nature communications
Published: May 20, 2021
Validation of ZMYND8 as a new treatment target in hepatocellular carcinoma.
Journal: Journal of cancer research and clinical oncology
Published: May 05, 2021
Validation of ORAOV1 as a new treatment target in hepatocellular carcinoma.
Journal: Journal of cancer research and clinical oncology
Published: August 12, 2020
New screening system using Twist1 promoter activity identifies dihydrorotenone as a potent drug targeting cancer-associated fibroblasts.
Journal: Scientific reports
Published: October 18, 2019
Drug repurposing screening identifies bortezomib and panobinostat as drugs targeting cancer associated fibroblasts (CAFs) by synergistic induction of apoptosis.
Journal: Investigational new drugs
Published: July 13, 2017
A positive feedback loop bi-stably activates fibroblasts.
Journal: Nature communications
Published: April 11, 2017
Twist1 is highly expressed in cancer-associated fibroblasts of esophageal squamous cell carcinoma with a prognostic significance.
Journal: Oncotarget
Published: August 15, 2016
Tenascin-C, a Prognostic Determinant of Esophageal Squamous Cell Carcinoma.
Journal: PloS one
Published: August 11, 2015
Twist1 is a key regulator of cancer-associated fibroblasts.
Journal: Cancer research
Published: November 05, 2014
Showing 1-12 of 12
Last Updated: 09/26/2026